|
Presenting Rocket, the Superhero Therapy Dog, a Touching Children’s Book by Dennis Erickson Dennis Erickson presents Rocket, the Superhero Therapy Dog, an exciting children’s book that draws inspiration from the real-life story of a caring therapy dog who brings comfort to the residents and staff at Eastview Health and Rehabilitation Center in Antigo, … Continue reading
|
Living Magazine voted Dr. Drew Moore of Village Periodontics & Implant Dentistry the #1 periodontist in Dallas Fort Worth, Texas. Village Periodontics & Implant Dentistry, led by Dr. Drew Moore, DDS, MS, is a periodontist in DFW focused on prevention … Continue reading
|
|
Dr. Jeremy Chan, DDS at Tempe Dentistry, an emergency dentist in Tempe, AZ focused on calm guidance, clear next steps, and prevention-first planning when urgent dental problems flare up. Tempe Dentistry, led by Dr. Jeremy Chan, DDS, is an emergency … Continue reading
|
Future Of Gaming: AI And Game Engine Innovations Dominate February Gaming Patent Filings AI AND GAME ENGINE INNOVATIONS DOMINATE FEBRUARY 2026 GAMING PATENT FILINGS Future Of Gaming: AI and Game Engine Innovations Dominate February 2026 Gaming Patent Filings PRAGUE – March 10, 2026 – Future of Gaming (FutureOfGaming.com) Publications today released its February 2026 … Continue reading
|
|
TECVAYLI + DARZALEX FASPRO FDA Approval Johnson & Johnson (NYSE: JNJ)’s Phase 3 MajesTEC-3 data show an 83% reduction in risk of disease progression or death, with 83.3% of patients alive at three years reshaping the multiple myeloma treatment paradigm … Continue reading
|
FDA Orphan Drug Designation for GENFIT’s G1090N With no approved therapy for Acute-on-Chronic Liver Failure (ACLF) and approximately 62K cases recorded across major markets, this FDA designation of GENFIT’s G1090N signals an accelerating race to address one of hepatology’s most … Continue reading
|
|
FDA Grants Priority Review to ENHERTU in Post-Neoadjuvant HER2-Positive Early Breast Cancer Phase III DESTINY-Breast05 data shows a 53% reduction in invasive disease recurrence or death vs. T-DM1, redefining the standard of care for nearly 16,000 annual post-neoadjuvant patients in … Continue reading
|
FDA Accepts NDA for Rusfertide and Grants Priority Review in Polycythemia Vera Takeda and Protagonist Therapeutics’ first-in-class hepcidin mimetic moves closer to market as FDA sets Q3 2026 PDUFA date; DelveInsight’s Polycythemia Vera Market Report tracks the full competitive and … Continue reading
|
|
Fidenti Wealth, widely recognized as a global leader in bespoke multi-family office services, has released its annual financial performance results, reporting $84 million in revenue for the fiscal year. The figure represents a 22% year-over-year increase, driven by the firm’s … Continue reading
|
This rebrand represents our evolution as a brand and our dedication to creating fragrances that don’t just smell beautiful but tell a story and transform ordinary moments into extraordinary experiences. Our new Parfum line showcases our commitment to craftsmanship and … Continue reading
|
